A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Reports FY24 revenue $36.13M, consensus $37.63M. “We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

"Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith ...

Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Welcome to the Revolution Medicines Q4 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the ...